Please assess the completion status of the following clinical trial:

Trial Title: Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active Rheumatoid Arthritis despite treatment with methotrexate~* Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening~* Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints~* Using methotrexate for at least 3 months prior to study enrollment~Exclusion Criteria:~* Patients having any systemic inflammatory condition~* Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis~* Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate within 4 weeks prior to screening~* Who have used corticosteroids within 4 weeks prior to screening~* Having received previous administration of infliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
- Infliximab 3 mg/kg every 8 weeks (Type: EXPERIMENTAL): Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
- Infliximab 3 mg/kg every 4 weeks (Type: EXPERIMENTAL): Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
- Infliximab 10 mg/kg every 8 weeks (Type: EXPERIMENTAL): Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
- Infliximab 10 mg/kg every 4 weeks (Type: EXPERIMENTAL): Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).